New hope for pancreatic cancer patients: drug combo trial shows promise
NCT ID NCT03404960
Summary
This study tested whether adding immunotherapy drugs (ipilimumab or nivolumab) to the cancer drug niraparib could help control advanced pancreatic cancer. It involved 104 patients whose cancer had initially responded to platinum-based chemotherapy but hadn't gotten worse. Researchers measured how long patients lived without their cancer growing and monitored side effects of the combination treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.